Company Encyclopedia
View More
name
Pasture
UUK.SG
Pasture Holdings Ltd. operates as a pharmaceutical products and medical supply company in Japan, Hong Kong, Canada, Singapore, and internationally. The company operates through three segments: Pharmaceutical Wholesale and Drop-Shipment; Masks and Medical Supplies; and Other Services. It is involved in the wholesale procurement and transshipment of pharmaceutical and nutraceutical products, such as vaccines and oncology treatments; and backend support of pharmaceutical supplies to international clients’ online pharmacy businesses.
60.64 M
UUK.SGMarket value -Rank by Market Cap -/-

Financial Score

18/12/2025 Update
C
Health Care DistributorsIndustry
Industry Ranking3/3
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE11.62%B
    • Profit Margin4.45%C
    • Gross Margin27.88%C
  • Growth ScoreD
    • Revenue YoY-15.60%E
    • Net Profit YoY-5.57%C
    • Total Assets YoY-25.24%E
    • Net Assets YoY5.74%B
  • Cash ScoreC
    • Cash Flow Margin2248.61%A
    • OCF YoY-15.60%E
  • Operating ScoreA
    • Turnover1.08A
  • Debt ScoreC
    • Gearing Ratio50.41%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    kopi-C with Pasture Holdings CEO: From pharma distributor to mask producer to drug delivery pioneer

    Lloyd Soong, CEO of Pasture Holdings, is leading the company into a new growth phase, focusing on pharmaceuticals and healthcare technology. The firm gained attention during the early Covid-19 pandemic for providing N95 masks in Singapore. As it approaches its 30th anniversary, Pasture aims to expand across ASEAN, enhance supply chain resilience, and develop products for chronic diseases and public health. Soong emphasizes trust and collaboration in partnerships, and highlights innovation in drug delivery, particularly with the oral disintegrating strip for patients with swallowing difficulties.

    SGX·
    SG
    UUK
    +49.02%
    SGX·
    SG
    UUK
    +49.02%

    Pasture Holdings Ltd Prepares for 2025 AGM, Engages with Stakeholders

    Pasture Holdings Ltd. (SG:UUK) has announced its Annual General Meeting (AGM) set for 23 October 2025, focusing on stakeholder engagement and transparency. The meeting will address questions from the Securities Investors Association (Singapore) and outline the company's strategic direction in the pharmaceuticals and medical supplies sector. Pasture Holdings specializes in over 1,000 pharmaceuticals and 1,200 medical supplies across 50 countries, and also develops proprietary products and offers cold-chain management services. The average trading volume for UUK stock is 24,962, with a technical sentiment signal indicating a 'Buy'.

    Tip Ranks·
    SG
    UUK
    +49.02%
    Tip Ranks·
    SG
    UUK
    +49.02%

    Pasture Holdings Expands into Malaysian Healthcare Market with Strategic Acquisition

    Pasture Holdings Ltd. has announced its acquisition of a 50% stake in AP Bioresources Sdn Bhd, a Malaysian company specializing in advanced medical devices. This strategic move aims to enhance Pasture's market presence in Malaysia and explore public healthcare opportunities, while improving supply chain capabilities and reducing operational risks. The acquisition aligns with Pasture's growth strategy in the ASEAN healthcare sector.

    Tip Ranks·
    SG
    UUK
    +49.02%
    Tip Ranks·
    SG
    UUK
    +49.02%

    Pasture Holdings Returns to Attributable Profit in Fiscal H1 as Revenue Soars 25%

    Pasture Holdings booked a profit attributable to owners of the company of $471,000 for the fiscal first half ended Dec. 31, 2024, against an attributable loss of $155,000 a year earlier, according to a filing with the Singapore Exchange on Thursday. Earnings per share came in at $0.0036, versus a loss per share of $0.0012 a year earlier. Revenue was up 25% year over year to $7.2 million from $5.7 million, driven by a marked growth in the pharmaceutical wholesale and mask and medical supplies segments.

    Trading View·
    SG
    UUK
    +49.02%
    Trading View·
    SG
    UUK
    +49.02%
    © 2025 Longbridge｜Disclaimer